Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2023-09-05 Call Transcript
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Call Transcript Classification · 90% confidence The document is a Form 8-K current report filed with the SEC, dated September 5, 2023. It announces positive top-line results from a Phase 3 clinical study and includes a press release and a slide presentation for a conference call. The document explicitly states that the information is not "filed" for purposes of the Exchange Act and is primarily an announcement of study results and an upcoming conference call. There are no detailed financial statements or comprehensive financial analysis included. The document length is 4112 characters, which is relatively short and consistent with an announcement rather than a full report. The presence of a slide presentation for a conference call and the nature of the content indicate this is a Call Transcript or related material. However, since the actual transcript is not included, but a presentation and announcement of the call are, the best fit is a Call Transcript (CT) category, which includes conference call materials and presentations related to earnings or study results. Therefore, the classification is CT with high confidence.
2023-09-05 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2023, reporting the issuance of a press release regarding financial results for the six months ended June 30, 2023. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results via a press release. The length is 3269 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial report or detailed analysis itself.
2023-08-03 English
Director's Dealing 2023
Director's Dealing
2023-07-13 English
Regulatory Filings 2023
Regulatory Filings
2023-07-11 English
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. The original Form 8-K reported the voting results of the company's annual meeting of shareholders held on May 11, 2023. This amendment discloses the company's decision on the frequency of future shareholder advisory votes on executive compensation (say on pay). The content focuses on the submission of matters to a vote of security holders and the voting results. There is no detailed financial data, no full annual or quarterly report, no earnings release, and no presentation. The document is primarily an official announcement of voting results from a shareholder meeting. According to the filing definitions, such documents fall under "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is under 5,000 characters and it contains substantive voting results, not just a report publication announcement. Therefore, the correct classification is DVA with high confidence.
2023-07-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.